semaglutide who makes it HealthMatters | What is semaglutide—and

An exception to this was the dimensional effect of metabolic risk on effort acceptance, which remained only marginally significant when controlling for current or past psychiatric disorders, suggesting the possibility that the metabolic effect on effort-based decision-making may, in part, be driven by psychiatric comorbidity, though statistical multicollinearity in this example makes that conclusion uncertain

Funding None of the authors received any funding for this manuscript

September 2025: Pfizer announced its agreement to acquire Metsera in a deal valued at up to USD 7.3 billion, strengthening its pipeline of next-generation GLP-1, amylin, and obesity therapies

Start your evaluation